BUY Biocon Ltd — Prakash Gaba
byPrakash GabaHorizon: NA (inferred Swing (≤2wk))17 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
RSI at 11 — oversold territory
Technicals · rsi·17 Sept · today
Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely seller
NewsEt-Markets·9 Sept · 1w ago
Biocon shares gain nearly 3% after equity worth ₹630 crore changes hands in block deal
NewsCnbc-Tv18·9 Sept · 1w ago
Biocon sees double-digit biosimilars growth continuing, targets mid-20% margins
NewsCnbc-Tv18·8 Sept · 1w ago
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
NewsEt-Markets·8 Sept · 1w ago
MACD below its signal line — bearish momentum
Technicals · macd·17 Sept · today
US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan
NewsGoogle News·16 Sept · today
Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal
NewsEt-Markets·8 Sept · 1w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.